Saved report copy
Recorded
OpenAI acquires Orchestra Bio to expand AI in biotech
OpenAI acquired AI biotech software startup Orchestra Bio on October 20, 2026, and will add its team and technology to the Rosalind life-sciences model and Rosalind Workbench tool used to plan experiments and analyze results. Financial terms were not disclosed; the four-year-old startup had raised about $20 million as of 2025, and its AI agents help pharmaceutical teams monitor studies, track drug-development finances and timelines, and flag potential delays. The deal advances OpenAI’s push into drug development, where it says Rosalind customers include Moderna and Novo Nordisk, as rival Anthropic expands its own life-sciences capabilities.
Reporting used